The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer

被引:17
作者
Mehta, Rutika [1 ]
Kommalapati, Anuhya [1 ]
Kim, Richard D. [1 ]
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL 33612 USA
来源
CANCER MANAGEMENT AND RESEARCH | 2020年 / 12卷
关键词
ramucirumab; gastric cancer; gastroesophageal junction cancer; quality of life; DOUBLE-BLIND; FUNCTIONAL ASSESSMENT; CHEMOTHERAPY; THERAPY; VALIDATION; QUESTIONNAIRE; TRIALS;
D O I
10.2147/CMAR.S199827
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Gastric cancer is the sixth most common cancer and is known to be the fifth-leading cause of cancer-related deaths globally in 2018. Systemic therapy remains the only curative option in advanced gastric carcinoma with the primary goal of improving the Health-related Quality of Life (HRQoL) (including palliation of symptoms such as dysphagia) and prolonging overall survival. Recently, ramucirumab is approved by the United States Food and Drug Administration (US-FDA) as a second-line agent either as monotherapy or in combination with paclitaxel in advanced or metastatic gastric and gastro-esophageal junction adenocarcinoma patients who have progressed on prior treatment with fluoropyrimidine or platinum containing chemotherapy. HRQoL is a subjective term that typically constitutes four components - psychological, social, occupational and physical well being. This has been evaluated as secondary endpoint in the pivotal Phase III trials with ramucirumab. HRQoL measurement can potentially provide additional information for clinical decision making beyond that of traditional medical outcomes. The present work is primarily focused on discussing HRQoL in gastric cancer patients and the impact of ramucirumab on the HRQoL in the patients with advanced gastric cancer. We also summarized the studies that evaluated the benefits of systemic therapies on HRQoL in advanced gastric cancer.
引用
收藏
页码:51 / 57
页数:7
相关论文
共 37 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[3]   Impact of Chemotherapy on Quality of Life in Patients With Metastatic Esophagogastric Cancer [J].
Al-Batran, Salah-Eddin ;
Ajani, Jaffer A. .
CANCER, 2010, 116 (11) :2511-2518
[4]  
[Anonymous], ANN ONCOL S8
[5]  
[Anonymous], ANN ONCOL S5
[6]  
[Anonymous], J NATL CANC I
[7]   Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer [J].
Blazeby, JM ;
Conroy, T ;
Bottomley, A ;
Vickery, C ;
Arraras, J ;
Sezer, O ;
Moore, J ;
Koller, M ;
Turhal, NS ;
Stuart, R ;
van Cutsem, E ;
D'haese, S ;
Coens, C .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) :2260-2268
[8]   Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols The SPIRIT-PRO Extension [J].
Calvert, Melanie ;
Kyte, Derek ;
Mercieca-Bebber, Rebecca ;
Slade, Anita ;
Chan, An-Wen ;
King, Madeleine T. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (05) :483-494
[9]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[10]   Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials [J].
Chau, Ian ;
Fuchs, Charles S. ;
Ohtsu, Atsushi ;
Barzi, Afsaneh ;
Liepa, Astra M. ;
Cui, Zhanglin Lin ;
Hsu, Yanzhi ;
Al-Batran, Salah-Eddin .
EUROPEAN JOURNAL OF CANCER, 2019, 107 :115-123